We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

Skip to main content
  • Register
  • Help
  • Contact us

Corbus Pharmaceuticals Holdings Inc (CRBP) USD0.0001

Sell:$0.80 Buy:$0.81 Change: $0.0629 (7.28%)
Market closed |  Prices as at close on 1 December 2021 | Switch to live prices |
Sell:$0.80
Buy:$0.81
Change: $0.0629 (7.28%)
Market closed |  Prices as at close on 1 December 2021 | Switch to live prices |
Sell:$0.80
Buy:$0.81
Change: $0.0629 (7.28%)
Market closed |  Prices as at close on 1 December 2021 | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

Corbus Pharmaceuticals Holdings, Inc. is a Phase-III, clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics that target the endocannabinoid system in the fields of autoimmunity, fibrosis, and cancer. It develops a diverse pipeline of drug candidates across programs, including small molecules as well as biologics. The Company's lead product candidate, Lenabasum, a novel, synthetic, oral, cannabinoid receptor type 2 (CB2) agonist designed to resolve chronic inflammation, limit fibrosis and support tissue repair. Lenabasum is in clinical development for treatment of autoimmune diseases. It is evaluating lenabasum and is in a Phase III study in dermatomyositis, as well as a Phase II study in systemic lupus erythematosus (SLE). It designs cannabinoid receptor type 1 (CB1) inverse agonists to normalize metabolic abnormalities or limit inflammation and fibrosis.

Contact details

Address:
500 RIVER RIDGE DRIVE
NORWOOD
02062
United States
Telephone:
+1 (617) 9630103
Website:
https://www.corbuspharma.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
CRBP
ISIN:
US21833P1030
Market cap:
$108.14 million
Shares in issue:
125.23 million
Sector:
Biotechnology
Exchange:
NASDAQ
Country:
United States
Currency:
US dollar
Indices:
n/a

Key personnel

  • Alan Holmer
    Independent Chairman of the Board
  • Yuval Cohen
    Chief Executive Officer, Director
  • Sean Moran
    Chief Financial Officer
  • Craig Millian
    Chief Operating Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.